AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition comprising a substance that inhibits secretase activity.

2. (Original) The pharmaceutical composition according to claim 1, wherein the secretase is β-secretase or γ-secretase.

3. (Original) The pharmaceutical composition according to claim 1 or 2, wherein the substance that inhibits secretase activity is a substance that promotes the sensitivity of a secretase inhibitor.

4. (Original) The pharmaceutical composition according to claim 3, wherein the substance that promotes the sensitivity of a secretase inhibitor is a substance that inhibits expression of synoviolin.

5. (Original) The pharmaceutical composition according to claim 4, wherein the substance that inhibits expression of synoviolin is siRNA or shRNA for a gene coding for synoviolin.

6. (Original) The pharmaceutical composition according to claim 5, wherein the gene coding for synoviolin comprises the nucleotide sequence represented by SEQ ID NO: 1.

7. (Original) The pharmaceutical composition according to claim 5, wherein the siRNA targets part of the nucleotide sequence represented by SEQ ID NO: 1.

8. (Original) The pharmaceutical composition according to claim 7, wherein the part of the nucleotide sequence is at least one selected from the nucleotide sequences represented by SEQ ID NOS: 3-16.

9. (Original) The pharmaceutical composition according to claim 1 or 2 wherein the substance that inhibits secretase activity is synoviolin.

10. (Cancelled).

11. (Cancelled).

12. (Original) A method for inhibiting secretase activity wherein the sensitivity of a secretase inhibitor is promoted.

13. (Original) The method according to claim 12, wherein the sensitivity of a secretase inhibitor is promoted by inhibiting expression of synoviolin.

14. (Original) A method for inhibiting secretase activity wherein synoviolin is bound to Herp.

15. (Original) The method according to claim 14, wherein the binding region of Herp with synoviolin is the region represented by amino acid residues Nos. 161-200 in the amino acid sequence of Herp.

16. (Original) The method according to any one of claims 12 through 15, wherein the secretase is β-secretase or γ-secretase.

17. (New) A method for treating a cerebro-neurological disease in a subject, comprising administering the subject an effective amount of the pharmaceutical composition of claim 8.

18. (New) The method of claim 17, wherein the cerebro-neurological disease is Alzheimer's disease.